Renzo Galanello
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Renzo Galanello has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Cao
Istituto di Clinica e Biologia dell'Età Evolutiva Università degli Studi di Cagliari, Ospedale Regionale Microcitemie, Cagliari, Italy
3 shared publications Susanna Barella
Dipartimento di Scienze Biomediche e Biotecnologie, Università degli Studi di Cagliari, Ospedale Regionale Microcitemie ASL8, Cagliari, Italy
2 shared publicationsAntonio Cao
Istituto di Clinica e Biologia dell'Etè Evolutiva, Ospedale Regionale per le Microcitemie Azienda A.S.L., 8 Cagliari, Italy
1 shared publicationFederica Deidda
1 shared publicationFranca Rosa Demartis
Dipartimento di Scienze Biomediche e Biotecnologie, Università degli Studi di Cagliari, Ospedale Regionale Microcitemie ASL8, Cagliari, Italy
1 shared publicationLaura Manunza
Dipartimento di Scienze Biomediche e Biotecnologie, Università degli Studi di Cagliari, Ospedale Regionale Microcitemie ASL8, Cagliari, Italy
1 shared publication
Latest Publications
- 20 October 2011
- Published by American Society of Hematology in Blood
- Vol. 118 (16) , 4454-4458
KLF1 gene mutations cause borderline HbA2
Increased hemoglobin A2 (HbA2; ie, levels > 3.9%) is the most important feature of β-thalassemia carriers. However, it is not uncommon to find persons with borderline HbA2 (levels, 3.3%-3.8%), who pose a relevant screening problem. Several genotypes have been associated with borderline HbA2, but sometimes the reasons for this unusual phenotype are unknown. In this paper, we report, for the first time, that mutations of KLF1 result in HbA2 levels in the borderline range. Six different KLF1 mutations were identified in 52 of 145 subjects with borderline HbA2 and normal mean corpuscular volume and mean corpuscular hemoglobin. Two mutations (T327S and T280_H283del) are here reported for the first time. The prevalent mutation in Sardinians is S270X, which accounts for 80.8% of the total. The frequent discovery of KLF1 mutations in these atypical carriers may contribute significantly to the thalassemia screening programs aimed at identification of at risk couples.
- 20 October 2011
- Published by American Society of Hematology in Blood
- Vol. 118 (16) , 4454-4458
KLF1 gene mutations cause borderline HbA2
Increased hemoglobin A2 (HbA2; ie, levels > 3.9%) is the most important feature of β-thalassemia carriers. However, it is not uncommon to find persons with borderline HbA2 (levels, 3.3%-3.8%), who pose a relevant screening problem. Several genotypes have been associated with borderline HbA2, but sometimes the reasons for this unusual phenotype are unknown. In this paper, we report, for the first time, that mutations of KLF1 result in HbA2 levels in the borderline range. Six different KLF1 mutations were identified in 52 of 145 subjects with borderline HbA2 and normal mean corpuscular volume and mean corpuscular hemoglobin. Two mutations (T327S and T280_H283del) are here reported for the first time. The prevalent mutation in Sardinians is S270X, which accounts for 80.8% of the total. The frequent discovery of KLF1 mutations in these atypical carriers may contribute significantly to the thalassemia screening programs aimed at identification of at risk couples.
- 1 March 2002
- Vol. 87 (3) , 242-5
H63D mutation in the HFE gene increases iron overload in beta-thalassemia carriers.
Hereditary hemochromatosis (HH) is an autosomal recessive disorder of iron metabolism. The HFE gene implicated in this disorder has been identified on chromosome 6 (6p21.3). The most prevalent mutation in HH patients changes the 282 cysteine residue to tyrosine (C282Y). The role of a second mutation which changes the 63 histidine to aspartic acid (H63D) in iron overload has been controversial. The aim of this study was to evaluate the effect of the H63D mutation on the ferritin levels of beta-thalassemia carriers. beta-thalassemia carriers have a tendency to increase iron absorption because of mild anemia and slightly increased erythropoiesis. Differences in ferritin levels between homozygotes for H63D and wild type may indicate a modulator effect of the HFE mutation on iron absorption. We studied 152 healthy males, heterozygous for beta-thalassemia. Serum ferritin was measured by chemiluminescence. H63D genotypes were determined by digestion of polymerase chain reaction (PCR) products with MboI restriction enzyme. Forty-five subjects were H63D heterozygotes and four subjects were H63D homozygotes. Ferritin levels were (mean +/- SD): 250 +/- 138 microg/L in homozygotes for the wild type H/H; 295 +/- 186 microg/L in H/D heterozygotes; and 389 +/- 75 microg/L in homozygotes for the mutation D/D. The difference in ferritin values between H/H and D/D is statistically significant (p=0.022). beta-thalassemia carriers who are homozygotes for the H63D mutation have higher ferritin levels than beta-thalassemia carriers with the H/H genotype, suggesting that the H63D mutation may have a modulating effect on iron absorption.
- 1 March 2002
- Vol. 87 (3) , 242-5
H63D mutation in the HFE gene increases iron overload in beta-thalassemia carriers.
Hereditary hemochromatosis (HH) is an autosomal recessive disorder of iron metabolism. The HFE gene implicated in this disorder has been identified on chromosome 6 (6p21.3). The most prevalent mutation in HH patients changes the 282 cysteine residue to tyrosine (C282Y). The role of a second mutation which changes the 63 histidine to aspartic acid (H63D) in iron overload has been controversial. The aim of this study was to evaluate the effect of the H63D mutation on the ferritin levels of beta-thalassemia carriers. beta-thalassemia carriers have a tendency to increase iron absorption because of mild anemia and slightly increased erythropoiesis. Differences in ferritin levels between homozygotes for H63D and wild type may indicate a modulator effect of the HFE mutation on iron absorption. We studied 152 healthy males, heterozygous for beta-thalassemia. Serum ferritin was measured by chemiluminescence. H63D genotypes were determined by digestion of polymerase chain reaction (PCR) products with MboI restriction enzyme. Forty-five subjects were H63D heterozygotes and four subjects were H63D homozygotes. Ferritin levels were (mean +/- SD): 250 +/- 138 microg/L in homozygotes for the wild type H/H; 295 +/- 186 microg/L in H/D heterozygotes; and 389 +/- 75 microg/L in homozygotes for the mutation D/D. The difference in ferritin values between H/H and D/D is statistically significant (p=0.022). beta-thalassemia carriers who are homozygotes for the H63D mutation have higher ferritin levels than beta-thalassemia carriers with the H/H genotype, suggesting that the H63D mutation may have a modulating effect on iron absorption.
- 1 June 1998
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 850 (1) , 325-333
Relationship between Genotype and Phenotype: Thalassemia Intermediaa
Abstract: Thalassemia intermedia encompasses a number of clinical conditions ranging in severity from β‐thalassemia carrier state to transfusion‐dependent thalassemia major. The molecular bases of thalassemia intermedia, only partially defined, are very heterogeneous, but in general any factor able to reduce the globin‐chain imbalance results in a milder form of thalassemia. These factors are the presence of a silent or mild β‐thalassemia allele, associated with a high residual β‐globin production, and the coinheritance of α‐thalassemia or of genetic determinants that increase the γ‐chain production. Less frequent mechanisms are double heterozygosity for β‐thalassemia and triplicated α genes, and the presence of a hyperunstable hemoglobin variant. However, for a consistent number of β0‐thalassemia homozygotes with a thalassemia intermedia phenotype the modifying factor has not been defined yet. In contrast, there are simple β‐thalassemia carriers who, for unknown reasons, have an unusually severe clinical phenotype.
- 1 June 1998
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 850 (1) , 325-333
Relationship between Genotype and Phenotype: Thalassemia Intermediaa
Abstract: Thalassemia intermedia encompasses a number of clinical conditions ranging in severity from β‐thalassemia carrier state to transfusion‐dependent thalassemia major. The molecular bases of thalassemia intermedia, only partially defined, are very heterogeneous, but in general any factor able to reduce the globin‐chain imbalance results in a milder form of thalassemia. These factors are the presence of a silent or mild β‐thalassemia allele, associated with a high residual β‐globin production, and the coinheritance of α‐thalassemia or of genetic determinants that increase the γ‐chain production. Less frequent mechanisms are double heterozygosity for β‐thalassemia and triplicated α genes, and the presence of a hyperunstable hemoglobin variant. However, for a consistent number of β0‐thalassemia homozygotes with a thalassemia intermedia phenotype the modifying factor has not been defined yet. In contrast, there are simple β‐thalassemia carriers who, for unknown reasons, have an unusually severe clinical phenotype.
- 15 September 1994
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 331 (11) , 746-747
Induction of Fetal Hemoglobin in the Presence of Increased 3-Hydroxybutyric Acid Associated with β-Ketothiolase Deficiency
Elevated levels of fetal hemoglobin may diminish the severity of the β-hemoglobinopathies sickle cell disease and β-thalassemia. In β-thalassemia, this effect is related to a reduction in the overall imbalance in the ratio of α-globin and non-α-globin chains. In sickle cell anemia, an elevated level of fetal hemoglobin results in a reciprocal decrease in the intracellular concentration of hemoglobin S and inhibits polymer formation. The discovery that butyric acid is an inducer of fetal hemoglobin arose from the observation that the switch from hemoglobin F to hemoglobin A is delayed in infants of diabetic mothers. In these newborns elevated plasma concentrations of a labile analogue of butyric acid, α-amino-n-butyric acid, were reported1.
- 15 September 1994
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 331 (11) , 746-747
Induction of Fetal Hemoglobin in the Presence of Increased 3-Hydroxybutyric Acid Associated with β-Ketothiolase Deficiency
Elevated levels of fetal hemoglobin may diminish the severity of the β-hemoglobinopathies sickle cell disease and β-thalassemia. In β-thalassemia, this effect is related to a reduction in the overall imbalance in the ratio of α-globin and non-α-globin chains. In sickle cell anemia, an elevated level of fetal hemoglobin results in a reciprocal decrease in the intracellular concentration of hemoglobin S and inhibits polymer formation. The discovery that butyric acid is an inducer of fetal hemoglobin arose from the observation that the switch from hemoglobin F to hemoglobin A is delayed in infants of diabetic mothers. In these newborns elevated plasma concentrations of a labile analogue of butyric acid, α-amino-n-butyric acid, were reported1.